Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings

Core Viewpoint - Twist Bioscience Corporation is expected to report a quarterly loss of 50 cents per share, an improvement from a loss of 59 cents per share a year ago, with projected revenue of $97.36 million, up from $84.71 million last year [1] Financial Performance - The anticipated quarterly loss for Twist Bioscience is 50 cents per share, compared to a loss of 59 cents per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $97.36 million, reflecting a year-over-year increase from $84.71 million [1] Stock Performance - Shares of Twist Bioscience declined by 6.2%, closing at $29.90 [2] Analyst Ratings - Stephens & Co. initiated coverage with an Overweight rating and a price target of $41 [6] - Goldman Sachs maintained a Buy rating but reduced the price target from $55 to $48 [6] - Guggenheim reiterated a Buy rating with a price target of $50 [6] - Baird maintained an Outperform rating and lowered the price target from $54 to $44 [6] - JP Morgan maintained an Underweight rating and cut the price target from $40 to $33 [6]